| ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells S Guedan, X Chen, A Madar, C Carpenito, SE McGettigan, MJ Frigault, ... Blood, The Journal of the American Society of Hematology 124 (7), 1070-1080, 2014 | 449 | 2014 |
| Soluble member (s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma N Scholler, N Fu, YI Yang, Z Ye, GE Goodman, KE Hellström, I Hellström Proceedings of the National Academy of Sciences 96 (20), 11531-11536, 1999 | 408 | 1999 |
| Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens DW Cramer, RC Bast Jr, CD Berg, EP Diamandis, AK Godwin, P Hartge, ... Cancer prevention research 4 (3), 365-374, 2011 | 397 | 2011 |
| A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor K Urbanska, E Lanitis, M Poussin, RC Lynn, BP Gavin, S Kelderman, J Yu, ... Cancer research 72 (7), 1844-1852, 2012 | 377 | 2012 |
| A mouse to human search for plasma proteome changes associated with pancreatic tumor development VM Faca, KS Song, H Wang, Q Zhang, AL Krasnoselsky, LF Newcomb, ... PLoS medicine 5 (6), e123, 2008 | 316 | 2008 |
| CA125 in ovarian cancer N Scholler, N Urban Biomarkers in medicine 1 (4), 513-523, 2007 | 282 | 2007 |
| Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma JN Brudno, N Lam, D Vanasse, Y Shen, JJ Rose, J Rossi, A Xue, A Bot, ... Nature medicine 26 (2), 270-280, 2020 | 278 | 2020 |
| Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study GL Anderson, M McIntosh, L Wu, M Barnett, G Goodman, JD Thorpe, ... Journal of the National Cancer Institute 102 (1), 26-38, 2010 | 266 | 2010 |
| Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma MW McIntosh, C Drescher, B Karlan, N Scholler, N Urban, KE Hellstrom, ... Gynecologic oncology 95 (1), 9-15, 2004 | 261 | 2004 |
| Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer MR Andersen, BA Goff, KA Lowe, N Scholler, L Bergan, CW Drescher, ... Gynecologic oncology 116 (3), 378-383, 2010 | 233 | 2010 |
| Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor E Lanitis, M Poussin, IS Hagemann, G Coukos, R Sandaltzopoulos, ... Molecular Therapy 20 (3), 633-643, 2012 | 223 | 2012 |
| A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer CS Zhu, PF Pinsky, DW Cramer, DF Ransohoff, P Hartge, RM Pfeiffer, ... Cancer prevention research 4 (3), 375-383, 2011 | 211 | 2011 |
| Bead-based ELISA for validation of ovarian cancer early detection markers N Scholler, M Crawford, A Sato, CW Drescher, KC O'Briant, N Kiviat, ... Clinical cancer research 12 (7), 2117-2124, 2006 | 200 | 2006 |
| Cutting edge: CD83 regulates the development of cellular immunity N Scholler, M Hayden-Ledbetter, A Dahlin, I Hellstrom, KE Hellström, ... The Journal of Immunology 168 (6), 2599-2602, 2002 | 173 | 2002 |
| Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders CL Law, AF Wahl, N Scholler, LA Pestano US Patent 7,662,387, 2010 | 159 | 2010 |
| A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy R Upadhyay, JA Boiarsky, G Pantsulaia, J Svensson-Arvelund, MJ Lin, ... Cancer discovery 11 (3), 599-613, 2021 | 156 | 2021 |
| Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses D Dangaj, E Lanitis, A Zhao, S Joshi, Y Cheng, R Sandaltzopoulos, HJ Ra, ... Cancer research 73 (15), 4820-4829, 2013 | 155 | 2013 |
| Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization S Nunez-Cruz, PA Gimotty, MW Guerra, DC Connolly, YQ Wu, ... Neoplasia 14 (11), 994-IN1, 2012 | 151 | 2012 |
| Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125 CA Shah, KA Lowe, P Paley, E Wallace, GL Anderson, MW McIntosh, ... Cancer Epidemiology Biomarkers & Prevention 18 (5), 1365-1372, 2009 | 148 | 2009 |
| Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma N Scholler, R Perbost, FL Locke, MD Jain, S Turcan, C Danan, EC Chang, ... Nature medicine 28 (9), 1872-1882, 2022 | 140 | 2022 |
George CoukosUniversity Hospital of Lausanne, Ludwig Institute for Cancer ResearchVerified email at chuv.ch
